Results 31 to 40 of about 5,054 (206)

Efficacy and safety of guselkumab in Chinese patients with moderate-to-severe plaque psoriasis: A randomized, double-blind, placebo-controlled trial

Chinese Medical Journal
. Background:. Guselkumab is effective in treating moderate-to-severe plaque psoriasis; however, data from randomized controlled trials in the Chinese population are limited.
Kun Huang, Songmei Geng, Xiaohua Tao, Liangdan Sun, Chao Ji, Bin Yang, Yan Lu, Rong Xiao, Chunlei Zhang, Furen Zhang, Qianjin Lu, Jie Zheng, Huiping Wang, Yuling Shi, Zhiming Li, Wei Yan, Litao Zhang, Juan Tao, Shoumin Zhang, Xiumin Yang, Hao Cheng, Jinhua Xu, Juan Su, Zhenying Zhang, Zhiqiang Song, Lu Wang, Rui Wang, Tong Zhang, Weilong Zhao, Yuhan Huang, Ming Chen, Zhongqi Dong, Shu Lyu, Min Zheng, Lishao Guo   +34 more
doaj   +1 more source

Pooled safety results through 1 year of 2 phase iii trials of guselkumab in patients with psoriatic arthritis [PDF]

, 2021
Objective: Evaluate the safety of guselkumab (monoclonal antibody targeting interleukin [IL]-23p19) in patients with psoriatic arthritis (PsA) through 1 year (1Y) of the phase III DISCOVER-1 and DISCOVER-2 trials. Methods: Patients with active PsA (n =
Helliwell, Philip S., Zhou, Bei, Hsia, Elizabeth C., Helliwell, Philip S, Ramachandran, Paraneedharan, Xu, Xie L, Zhuang, Yanli, Gottlieb, Alice B, McInnes, Iain B., Kafka, Shelly, Gottlieb, Alice B., Hsia, Elizabeth C, Boehncke, Wolf-Henning, Mease, Philip J., Rahman, Proton, Mease, Philip J, Shawi, May, Agarwal, Prasheen, McInnes, Iain B, Ritchlin, Christopher T, Ritchlin, Christopher T., Kollmeier, Alexa P., Xu, Xie L., Sheng, Shihong, Kollmeier, Alexa P   +24 more
core   +1 more source

Paradoxical Psoriatic Arthritis with the Initiation of Brodalumab and Guselkumab [PDF]

, 2020
Paradoxical plaque psoriasis reactions have been reported with the usage of biologics, primarily with the use of anti-TNF agents. Brodalumab, a human monoclonal antibody against interleukin-17 receptor A (IL17RA), and, guselkumab, an interleukin-23 ...
Slater, Kristin, Kartono, Francisca, Kashlan, Reem   +2 more
core   +1 more source

Clinical utility of guselkumab in the treatment of moderate-to-severe plaque psoriasis [PDF]

, 2021
Psoriasis is a chronic immune-mediated disease involving complex interaction of T cells and keratinocytes. The comprehensive pathogenesis of psoriasis is not fully under-stood but the IL-23/Th17 axis is a central pathway in driving disease development ...
Su, Jennifer J., Feldman, Steven R., Light, Jeremy G.   +2 more
core   +1 more source

Efficacy of Guselkumab in Treating Nails, Scalp, Hands, and Feet in Patients with Psoriasis and Self-reported Psoriatic Arthritis

Dermatology and Therapy, 2023
Introduction The aim of this study was to evaluate guselkumab efficacy on regional psoriasis in a subset of psoriasis patients with a self-reported psoriatic arthritis (PsA) diagnosis.
Ana-Maria Orbai, Soumya D. Chakravarty, Yin You, May Shawi, Ya-Wen Yang, Joseph F. Merola   +5 more
doaj   +1 more source

Matching-adjusted indirect comparison (MAIC) results confirmed by head-to-head trials: a case study in psoriasis

Journal of Dermatological Treatment, 2023
Background Head-to-head comparisons through randomized controlled trials (RCTs) provide high-quality evidence to inform healthcare decisions. In their absence, indirect comparisons are often performed; however, evidence is limited on how valid matching ...
James Signorovitch, Joris Diels, Suzy Van Sanden, Agata Schubert, Fareen Hassan, Pushpike Thilakarathne, Bulent Ozturk, Norma Barthelmes, Kristian Reich   +8 more
doaj   +1 more source

From Adult to Adolescent: Alignment in Clinical Trials and Outcomes in Axial Spondyloarthritis

Arthritis Care &Research, EarlyView.
Spondyloarthritis (SpA) is a group of chronic inflammatory diseases encompassing axial and peripheral forms, with up to 20% of patients developing symptoms before age 16. Despite this substantial pediatric burden, treatment options for juvenile‐onset SpA (JSpA), particularly those with axial disease (axJSpA), remain limited.
Pamela F. Weiss, Judith A. Smith, Robert A. Colbert, Erin Treemarcki, Michael H. Weisman, Walter P. Maksymowych, Hermine I. Brunner, for the Childhood Arthritis and Rheumatology Research Alliance, Spondyloarthritis Research and Treatment Network, and Pediatric Rheumatology Collaborative Study Group Advisory Council   +9 more
wiley   +1 more source

Comparing Efficacy of Guselkumab versus Ustekinumab in Patients with Psoriatic Arthritis: An Adjusted Comparison Using Individual Patient Data from the DISCOVER and PSUMMIT Trials

Rheumatology and Therapy
Introduction Two biologic therapies for psoriatic arthritis (PsA), guselkumab and ustekinumab, have demonstrated superior efficacy versus placebo in clinical trials.
Pushpike Thilakarathne, Agata Schubert, Steve Peterson, Wim Noel, Barkha P. Patel, Fareen Hassan   +5 more
doaj   +1 more source

Combination Therapy in Participants With Active Psoriatic Arthritis Using Subcutaneous Guselkumab and Golimumab: Week 24 Results From a Phase 2a, Multicenter, Randomized, Double‐Blind, Proof‐of‐Concept Study

Arthritis &Rheumatology, EarlyView.
Objective To assess guselkumab + golimumab combination therapy versus guselkumab monotherapy in participants with active psoriatic arthritis (PsA) and inadequate response to tumor necrosis factor inhibitors (TNFi‐IR). Methods Adults with active TNFi‐IR PsA (three or more tender/swollen joints) were randomized (2:1) to subcutaneous guselkumab (100 mg) +
Jose U. Scher, Iain B. McInnes, Enrique R. Soriano, Joseph F. Merola, Paul Bird, Vinod Chandran, Edaire Cheng, Elena Reynoso, Warner Chen, Maoji Li, Lianne S. Gensler, Philip J. Mease, Christopher T. Ritchlin   +12 more
wiley   +1 more source

Guselkumab Reduces Disease- and Mechanism-Related Biomarkers More Than Adalimumab in Patients with Psoriasis: A VOYAGE 1 Substudy

JID Innovations
Background: Psoriasis is an immune-mediated inflammatory disease characterized by activation of IL-23–driven IL-17–producing T cell and other IL-23 receptor–positive IL-17–producing cell responses.
Andrew Blauvelt, Richard G. Langley, Patrick J. Branigan, Xuejun Liu, Yanqing Chen, Samuel DePrimo, Keying Ma, Brittney Scott, Kim Campbell, Ernesto J. Muñoz-Elías, Kim A. Papp   +10 more
doaj   +1 more source